000099081 001__ 99081
000099081 005__ 20210902121940.0
000099081 0247_ $$2doi$$a10.2147/IDR.S282880
000099081 0248_ $$2sideral$$a122350
000099081 037__ $$aART-2020-122350
000099081 041__ $$aeng
000099081 100__ $$aDel Rosal, T.
000099081 245__ $$aStaphylococcus aureus nasal colonization in Spanish children. The COSACO nationwide surveillance study
000099081 260__ $$c2020
000099081 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099081 5203_ $$aObjective: To assess the prevalence and risk factors for S. aureus and methicillin-resistant S. aureus (MRSA) nasal colonization in Spanish children.
Methods: Cross-sectional study of patients <14 years from primary care centers all over Spain. Clinical data and nasal aspirates were collected from March to July 2018.
Results: A total of 1876 patients were enrolled. Prevalence of S. aureus and MRSA colonization were 33% (95% CI 30.9–35.1) and 1.44% (95% CI 0.9–2), respectively. Thirtythree percent of the children (633/1876) presented chronic conditions, mainly atopic dermatitis, asthma and/or allergy (524/633). Factors associated with S. aureus colonization were age =5 years (OR 1.10, 95% CI 1.07–1.12), male sex (OR 1.43, 95% CI 1.17–1.76), urban setting (OR 1.46, 95% CI 1.08–1.97) and the presence of asthma, atopic dermatitis or allergies (OR 1.25; 95% CI: 1.093–1.43). Rural residence was the only factor associated with MRSA colonization (OR 3.62, 95% CI 1.57–8.36). MRSA was more frequently resistant than methicillin-susceptible S. aureus to ciprofloxacin [41.2% vs 2.6%; p<0.0001], clindamycin [26% vs 16.9%; p=0.39], and mupirocin [14.3% vs 6.7%; p=0.18]. None of the MRSA strains was resistant to tetracycline, fosfomycin, vancomycin or daptomycin.
Conclusions: The main risk factors for S. aureus colonization in Spanish children are being above five years of age, male gender, atopic dermatitis, asthma or allergy, and residence in urban areas. MRSA colonization is low, but higher than in other European countries and is associated with rural settings.
000099081 536__ $$9info:eu-repo/grantAgreement/ES/MICINN-ISCIII-FEDER-FIS/PI18CIII-00372
000099081 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000099081 590__ $$a4.003$$b2020
000099081 591__ $$aPHARMACOLOGY & PHARMACY$$b111 / 275 = 0.404$$c2020$$dQ2$$eT2
000099081 591__ $$aINFECTIOUS DISEASES$$b35 / 92 = 0.38$$c2020$$dQ2$$eT2
000099081 592__ $$a1.032$$b2020
000099081 593__ $$aInfectious Diseases$$c2020$$dQ1
000099081 593__ $$aPharmacology (medical)$$c2020$$dQ1
000099081 593__ $$aPharmacology$$c2020$$dQ1
000099081 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099081 700__ $$aEchevarría, A.M.
000099081 700__ $$0(orcid)0000-0002-8459-9705$$aGarcia-Vera, C.$$uUniversidad de Zaragoza
000099081 700__ $$aEscosa-Garcia, L.
000099081 700__ $$aAgud, M.
000099081 700__ $$aChaves, F.
000099081 700__ $$aRomán, F.
000099081 700__ $$aGutierrez-Fernandez, J.
000099081 700__ $$ade Gopegui, E.R.
000099081 700__ $$aRuiz-Carrascoso, G.
000099081 700__ $$aRuiz-Gallego, M.C.
000099081 700__ $$aBernet, A.
000099081 700__ $$aQuevedo, S.M.
000099081 700__ $$aFernández-Verdugo, A.M.
000099081 700__ $$aDíez-Sebastian, J.
000099081 700__ $$aCalvo, C.
000099081 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría
000099081 773__ $$g13 (2020), 4643-4651$$pInfect. drug resist.$$tInfection and Drug Resistance$$x1178-6973
000099081 8564_ $$s285269$$uhttps://zaguan.unizar.es/record/99081/files/texto_completo.pdf$$yVersión publicada
000099081 8564_ $$s2725008$$uhttps://zaguan.unizar.es/record/99081/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099081 909CO $$ooai:zaguan.unizar.es:99081$$particulos$$pdriver
000099081 951__ $$a2021-09-02-11:01:04
000099081 980__ $$aARTICLE